ArticleScientific reports2020
National burden of cancer in Italy, 1990-2017: a systematic analysis for the global burden of disease study 2017.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Area-based centralization of pancreatic surgery: a Hub-and-Spoke system balances patient proximity and quality of care.Updates in surgery · 2026Article
- Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies.Frontiers in oncology · 2026Article
- The national and subnational burden of Non-Hodgkin Lymphomas (NHL) in Italy from 1990 to 2023: results from the Global Burden of Disease Study 2023.EClinicalMedicine · 2025Article
- The national and subnational burden of multiple myeloma (MM) in Italy from 1990 to 2023: results from the global burden of disease study 2023.EClinicalMedicine · 2025Article
- The national and subnational burden of Hodgkin Lymphoma (HL) in Italy from 1990 to 2023: results from the Global Burden of Disease Study 2023.EClinicalMedicine · 2025Article
- The national burden of Leukemia in Italy from 1990 to 2023: results from the Global Burden of Disease Study 2023.EClinicalMedicine · 2025Article
- State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021.The Lancet. Public health · 2025Article
- Geographic disparities in gastrointestinal oncology research: a focus on trial availability in Italy.The oncologist · 2025Article
- Investigation Cytotoxicity and Curcumin Release Behavior by Pyranopyrazole-TiOApplied biochemistry and biotechnology · 2024Article
- Lung cancer and smoking: years lived with disability in Tuscany (Italy). An analysis from the ACAB study.BMC public health · 2024Article
- Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma.Life (Basel, Switzerland) · 2024Review
- Article
- Trend and Joinpoint Analysis of Cancer Incidence and 1-Year Mortality in North-East Spain 2005-2020.Cancers · 2023Article
- Article
- Article
- National Burden and Trend of Cancer in Ethiopia, 2010-2019: a systemic analysis for Global burden of disease study.Scientific reports · 2022Article
- Alarmists at the Gates: Esophageal Adenocarcinoma after Sleeve Gastrectomy is Not Different than with Other Bariatric/Metabolic Surgeries.Obesity surgery · 2022Article
- The non-fatal burden of cancer in Belgium, 2004-2019: a nationwide registry-based study.BMC cancer · 2022Article
- Returning to work after a sickness absence due to cancer: a cohort study of salaried workers in Catalonia (Spain).Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We monitored the burden of cancer in Italy and its trends over the last three decades, providing estimates of cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs), for cancer overall and 30 cancer sites using data from the Global Burden of Disease study 2017. An overview of mortality trends between 1990 and 2017 was also provided. In 2017, there were 254,336 new cancer cases in men and 214,994 in women, corresponding to an age-standardized incidence rate (ASIR) of 438 and 330/100,000, respectively. Between 1990 and 2017, incident cancer cases, and, to a lesser extent, ASIRs significantly increased overall and for almost all cancer sites, but ASIRs significantly declined for lung and other tobacco-related neoplasms. In 2017, there were 101,659 cancer deaths in men (age-standardized death rate, ASDR, 158.5/100,000) and 78,918 in women (ASDR 93.9/100,000). Cancer deaths significantly increased between 1990 and 2017 (+ 18%), but ASDR significantly decreased (- 28%). Deaths significantly increased for many cancer sites, but decreased for stomach, esophageal, laryngeal, Hodgkin lymphoma, and testicular cancer. ASDRs significantly decreased for most neoplasms, with the main exceptions of cancer of the pancreas and uterus, and multiple myeloma. In 2017, cancer caused 3,204,000 DALYs. Between 1990 and 2017, DALYs and age-standardized DALY rates significantly declined (-3.4% and -33%, respectively). Age-standardized mortality rates in Italy showed favorable patterns over the last few decades. However, the absolute number of cancer cases and, to a lower extent, of cancer deaths increased likely due to the progressive ageing of the population, this calling for a continuous effort in cancer prevention, early diagnosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.